BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Figure 5. Actuarial prostate-specific antigen (PSA) relapse-free survival (RFS) according to ESTRO risk groups based on initial PSA and Gleason score prior to treatment. PSA-RFS is 84.3%, 73.9%, and 52.6% for patients cohorts of risk groups low, intermediate, and high, respectively (p≤0.0001) (solid line, low risk; dashed intermediate risk; dotted high risk).





Right arrow Return to article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS